NEW YORK (GenomeWeb) – Curetis reported today a 9 percent decline in revenues for the first half of 2017, reflecting market volatility for its Unyvero molecular diagnostic system.

For the six-month period ended June 30, Curetis' revenues fell to €594,800 ($695,176) from €654,682 in the first half of 2016. The firm said that due to the uneven spread of early-stage instrument sales throughout the year, revenue volatility is expected quarter to quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.